Skip to main content
. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347

Figure 3.

Figure 3

CD49d surface molecules levels and saturation percentage in CD4+ and CD8+ T lymphocytes, and CD19+ B lymphocytes in RRMS patients under Natalizumab treatment in SD or EID. Mean of (a) CD49d molecules/cell surface, (b) bound NTZ/cell surface, (c) free CD49d molecules/cell surface, and (d) CD49d saturation percentage in CD4+ and CD8+ T lymphocytes, and CD19+ B lymphocytes in the SD (n = 8) and EID (n = 21) groups. Each dot represents the number of PE molecules per cell for each patient in the first extraction (V1), translated into the levels of the corresponding antibodies (anti-CD49d PE and huIgG4 Fc PE). EID, extended interval dosing; NTZ, natalizumab; SD, standard dosing. Ns: p > 0.05, * p < 0.05, ** p < 0.01.